MusclePharm Investor Takes ‘Executive Role’ In Restructuring
This article was originally published in The Tan Sheet
Executive Summary
The firm’s restructuring also includes staff cuts and facility closings it expects will lead to annual cost savings greater than $20m and spur profitability starting in 2016 and operating profit margins of 10% by 2020. Ryan Drexler became chairman when he acquired a nearly 11% stake in June.